Hiba Therapeutics
A platform-based targeted strategy for solid cancers.
🧬 Pharmaceuticals & Drug Development
🧬 Pharmaceuticals & Drug Development
testing / soft commits
testing / soft commits
Invested$4,400
2%
Funding goal$250K
Minimum ticket$100
Investors-
Terms
Sign in to view terms
About Hiba Therapeutics
Developing a modular, programmable platform to harness tumor-resident T cells against cancer. The approach is based on validated science from Harvard and Mass General, with research published in leading journals.
The description cites superior head-to-head efficacy against best-in-class PD-1 therapies for aggressive cancers. The lead asset, HIB 117, is described as well tolerated and safe, with no detectable toxicities.
The company is based in Kendall Square, Cambridge, Massachusetts, a biotech hub. It is supported by the AI BioHub Accelerator Program, LabCentral, and Biolabs Golden Ticket, among others.
Fact Sheet
FoundedN/A
Industry
🧬 Pharmaceuticals & Drug Development
EmployeesN/A
Website
N/A
Social Media
N/A
Crowdfunding History
Total RaisedN/A
# RoundsN/A
Team
Shariq Usmani
Hiba TherapeuticsUnlock Full Campaign DetailsCreate a free account to access comprehensive investment data and make informed decisions.
Funding History
Financials
Investor Perks
Timeline
Team Members
Offering Terms